David M. Faleck

2.3k total citations
41 papers, 874 citations indexed

About

David M. Faleck is a scholar working on Oncology, Epidemiology and Genetics. According to data from OpenAlex, David M. Faleck has authored 41 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Epidemiology and 14 papers in Genetics. Recurrent topics in David M. Faleck's work include Cancer Immunotherapy and Biomarkers (21 papers), Microscopic Colitis (15 papers) and Inflammatory Bowel Disease (14 papers). David M. Faleck is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Microscopic Colitis (15 papers) and Inflammatory Bowel Disease (14 papers). David M. Faleck collaborates with scholars based in United States, United Kingdom and China. David M. Faleck's co-authors include Franck Carbonnel, Caroline Robert, Clélia Coutzac, Patricia Lepage, Lysiane Marthey, Michael Collins, Nathalie Chaput, Émilie Soularue, Jean Frederic Colombel and A. Ari Hakimi and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

David M. Faleck

39 papers receiving 868 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David M. Faleck United States 16 386 283 195 192 178 41 874
Wolfgang Kraaz Sweden 19 255 0.7× 391 1.4× 261 1.3× 259 1.3× 563 3.2× 34 1.3k
Tadashi Yokoyama Japan 16 242 0.6× 258 0.9× 302 1.5× 139 0.7× 363 2.0× 102 864
Jingmei Lin United States 18 371 1.0× 428 1.5× 165 0.8× 173 0.9× 375 2.1× 82 1.1k
Giuseppe Aimo Italy 16 108 0.3× 204 0.7× 133 0.7× 74 0.4× 190 1.1× 44 749
Junji Yokoyama Japan 19 131 0.3× 174 0.6× 121 0.6× 201 1.0× 492 2.8× 99 959
Domenico Piscitelli Italy 17 191 0.5× 191 0.7× 97 0.5× 205 1.1× 543 3.1× 85 1.0k
Xiaoyan Liao United States 16 254 0.7× 152 0.5× 103 0.5× 95 0.5× 311 1.7× 79 821
Hülya Çetınkaya Türkiye 17 139 0.4× 472 1.7× 209 1.1× 80 0.4× 162 0.9× 48 989
M. Henar Alonso United States 19 361 0.9× 108 0.4× 87 0.4× 220 1.1× 397 2.2× 42 1.0k
Norio Hirabayashi Japan 14 158 0.4× 89 0.3× 76 0.4× 144 0.8× 173 1.0× 41 820

Countries citing papers authored by David M. Faleck

Since Specialization
Citations

This map shows the geographic impact of David M. Faleck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Faleck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Faleck more than expected).

Fields of papers citing papers by David M. Faleck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Faleck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Faleck. The network helps show where David M. Faleck may publish in the future.

Co-authorship network of co-authors of David M. Faleck

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Faleck. A scholar is included among the top collaborators of David M. Faleck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Faleck. David M. Faleck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kamboj, Mini, et al.. (2025). Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network. 23(5). 147–155.
2.
Itzkowitz, Steven H., Yue Jiang, Cristina Villagra, et al.. (2024). Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry. Clinical Gastroenterology and Hepatology. 23(5). 855–865.e5. 5 indexed citations
3.
Thomas, Anusha Shirwaikar, Lu Yang, John A. Thompson, et al.. (2024). Immune Checkpoint Inhibitor–Induced Colitis. Gastroenterology. 168(1). 21–28. 1 indexed citations
4.
Valle, Diane M. Del, Graham J. Britton, Alice Chen-Liaw, et al.. (2024). Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. The Journal of Experimental Medicine. 222(1). 5 indexed citations
5.
Srivastava, Amitabh, et al.. (2024). Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 12(7). e009051–e009051. 3 indexed citations
6.
Lovasi, Gina S., et al.. (2023). Crohn’s Disease Mortality and Ambient Air Pollution in New York City. Inflammatory Bowel Diseases. 30(10). 1732–1739. 5 indexed citations
7.
Moy, Andrea P., et al.. (2023). IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events. Pharmaceuticals. 16(11). 1548–1548. 6 indexed citations
8.
Badran, Yousef R., Fangwen Zou, Sienna Durbin, et al.. (2023). Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. Journal for ImmunoTherapy of Cancer. 11(6). e007195–e007195. 17 indexed citations
9.
Lin, I‐Hsin, et al.. (2023). Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors. The Oncologist. 28(12). 1085–1093. 13 indexed citations
10.
Faleck, David M., et al.. (2023). Accelerating the Evolution of Immune-Related Enterocolitis Management. Journal of Clinical Oncology. 41(17). 3110–3115. 4 indexed citations
11.
Maron, Steven B., Stephanie King, Mark Schattner, et al.. (2023). Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 11(10). e007699–e007699. 38 indexed citations
12.
Elkrief, Arielle, John Slingerland, Melissa Lumish, et al.. (2023). Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.. Journal of Clinical Oncology. 41(16_suppl). 2657–2657. 4 indexed citations
13.
Kamboj, Mini, et al.. (2023). Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes. The Oncologist. 29(1). 36–46. 3 indexed citations
14.
Luo, Jia, Jason Beattie, Hira Rizvi, et al.. (2021). Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. Journal of Thoracic Oncology. 16(10). 1759–1764. 74 indexed citations
15.
Smithy, James W., David M. Faleck, & Michael A. Postow. (2021). Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. Clinical Cancer Research. 28(7). 1250–1257. 20 indexed citations
16.
Faleck, David M., Eugenia Shmidt, Ruiqi Huang, et al.. (2020). Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysis. Clinical Gastroenterology and Hepatology. 19(2). 238–245.e4. 17 indexed citations
17.
Soularue, Émilie, Patricia Lepage, Jean Frederic Colombel, et al.. (2018). Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 67(11). 2056–2067. 184 indexed citations
18.
Faleck, David M., Hojjat Salmasian, Yoko Furuya, et al.. (2016). Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit. The American Journal of Gastroenterology. 111(11). 1641–1648. 47 indexed citations
19.
Hakimi, A. Ari, et al.. (2011). Assessment of complication and functional outcome reporting in the minimally invasive prostatectomy literature from 2006 to the present. British Journal of Urology. 109(1). 26–30. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wolfgang Kraaz Breakdown of academic impact, for papers by Tadashi Yokoyama Breakdown of academic impact, for papers by Jingmei Lin Breakdown of academic impact, for papers by Giuseppe Aimo Breakdown of academic impact, for papers by Junji Yokoyama Breakdown of academic impact, for papers by Domenico Piscitelli Breakdown of academic impact, for papers by Xiaoyan Liao Breakdown of academic impact, for papers by Hülya Çetınkaya Breakdown of academic impact, for papers by M. Henar Alonso Breakdown of academic impact, for papers by Norio Hirabayashi
Rankless by CCL
2026